AU2013352594B2 - 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1H-pyrazol-3-yl}-ethyl)-3H-1,3-benzothiazol-2-one as a TARP-gamma 8 dependent AMPA receptor antagonist - Google Patents

6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1H-pyrazol-3-yl}-ethyl)-3H-1,3-benzothiazol-2-one as a TARP-gamma 8 dependent AMPA receptor antagonist Download PDF

Info

Publication number
AU2013352594B2
AU2013352594B2 AU2013352594A AU2013352594A AU2013352594B2 AU 2013352594 B2 AU2013352594 B2 AU 2013352594B2 AU 2013352594 A AU2013352594 A AU 2013352594A AU 2013352594 A AU2013352594 A AU 2013352594A AU 2013352594 B2 AU2013352594 B2 AU 2013352594B2
Authority
AU
Australia
Prior art keywords
compound
seizures
mammal
benzothiazol
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013352594A
Other languages
English (en)
Other versions
AU2013352594A1 (en
Inventor
Warren Jaye Porter
Jon Kevin Reel
Jeffrey Michael Witkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2013352594A1 publication Critical patent/AU2013352594A1/en
Application granted granted Critical
Publication of AU2013352594B2 publication Critical patent/AU2013352594B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2013352594A 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1H-pyrazol-3-yl}-ethyl)-3H-1,3-benzothiazol-2-one as a TARP-gamma 8 dependent AMPA receptor antagonist Active AU2013352594B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730273P 2012-11-27 2012-11-27
US61/730,273 2012-11-27
PCT/US2013/070885 WO2014085153A1 (en) 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}- ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist

Publications (2)

Publication Number Publication Date
AU2013352594A1 AU2013352594A1 (en) 2015-06-04
AU2013352594B2 true AU2013352594B2 (en) 2016-02-18

Family

ID=49753484

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013352594A Active AU2013352594B2 (en) 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1H-pyrazol-3-yl}-ethyl)-3H-1,3-benzothiazol-2-one as a TARP-gamma 8 dependent AMPA receptor antagonist

Country Status (35)

Country Link
US (1) US8765960B2 (enExample)
EP (1) EP2925754B1 (enExample)
JP (1) JP6246227B2 (enExample)
KR (1) KR101693133B1 (enExample)
CN (1) CN104797578B (enExample)
AP (1) AP2015008489A0 (enExample)
AR (1) AR093527A1 (enExample)
AU (1) AU2013352594B2 (enExample)
BR (1) BR112015011200A2 (enExample)
CA (1) CA2889243C (enExample)
CL (1) CL2015001419A1 (enExample)
CR (1) CR20150267A (enExample)
CY (1) CY1118657T1 (enExample)
DK (1) DK2925754T3 (enExample)
DO (1) DOP2015000113A (enExample)
EA (1) EA026686B1 (enExample)
ES (1) ES2618260T3 (enExample)
HR (1) HRP20170274T1 (enExample)
HU (1) HUE033447T2 (enExample)
IL (1) IL238831B (enExample)
JO (1) JO3225B1 (enExample)
MA (1) MA38126B1 (enExample)
MX (1) MX356478B (enExample)
MY (1) MY177721A (enExample)
PE (1) PE20151728A1 (enExample)
PH (1) PH12015501154B1 (enExample)
PL (1) PL2925754T3 (enExample)
PT (1) PT2925754T (enExample)
SG (1) SG11201504164VA (enExample)
SI (1) SI2925754T1 (enExample)
TN (1) TN2015000200A1 (enExample)
TW (2) TW201825484A (enExample)
UA (1) UA114345C2 (enExample)
WO (1) WO2014085153A1 (enExample)
ZA (1) ZA201503733B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
CA2984290C (en) * 2015-04-29 2022-03-01 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators
ES2865330T3 (es) * 2015-04-29 2021-10-15 Janssen Pharmaceutica Nv Azabenzimidazoles y su uso como moduladores del receptor AMPA
US10604484B2 (en) 2015-04-29 2020-03-31 Janssen Pharmaceutica Nv Indolone compounds and their use as AMPA receptor modulators
JP6800885B2 (ja) 2015-04-29 2020-12-16 ヤンセン ファーマシューティカ エヌ．ベー． イミダゾピラジン及びピラゾロピリミジン、並びにａｍｐａ受容体調節物質としてのこれらの使用
JP6953527B2 (ja) * 2016-10-26 2021-10-27 ヤンセン ファーマシューティカ エヌ．ベー． 縮合二環ピリジン化合物、及びａｍｐａ受容体調節因子としてのそれらの使用
RU2650523C1 (ru) * 2017-07-24 2018-04-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Производное пиридоксина для лечения эпилепсии
RU2703286C1 (ru) * 2019-06-18 2019-10-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Соли (5-гидрокси-3,4-бис(гидроксиметил)-6-метилпиридин-2-ил)метансульфокислоты и способ их получения

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1300396A1 (en) * 2000-06-12 2003-04-09 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
JP2000281676A (ja) * 1999-01-25 2000-10-10 Yamanouchi Pharmaceut Co Ltd Ａｍｐａ拮抗化合物の新規製造法
US8995993B2 (en) * 2000-10-11 2015-03-31 Gogo Llc System for managing mobile internet protocol addresses in an airborne wireless cellular network
ATE404555T1 (de) * 2004-12-17 2008-08-15 Lilly Co Eli Neue mch-rezeptorantagonisten
WO2007076161A2 (en) 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
JP2012505198A (ja) * 2008-10-08 2012-03-01 ファイザー・インク Ｃｎｓ障害を治療する際にａｍｐａ調節剤として使用するためのテトラヒドロフラニルスルホンアミド
HRP20150355T1 (hr) * 2009-01-12 2015-06-19 Pfizer Limited Sulfonamidni derivati
JP6088425B2 (ja) * 2010-06-01 2017-03-01 アンジオン バイオメディカ コーポレーション チトクロームｐ４５０阻害剤およびその使用
JP5976011B2 (ja) * 2011-04-05 2016-08-23 武田薬品工業株式会社 スルホンアミド誘導体およびその用途
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1300396A1 (en) * 2000-06-12 2003-04-09 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof

Also Published As

Publication number Publication date
PL2925754T3 (pl) 2017-07-31
US8765960B2 (en) 2014-07-01
EP2925754B1 (en) 2016-12-28
JP6246227B2 (ja) 2017-12-13
AR093527A1 (es) 2015-06-10
HK1209116A1 (en) 2016-03-24
TN2015000200A1 (en) 2016-10-03
PE20151728A1 (es) 2015-12-02
CA2889243A1 (en) 2014-06-05
TW201434834A (zh) 2014-09-16
EA201590823A1 (ru) 2015-08-31
WO2014085153A8 (en) 2014-07-31
AU2013352594A1 (en) 2015-06-04
MX356478B (es) 2018-05-30
BR112015011200A2 (pt) 2017-07-11
CL2015001419A1 (es) 2015-10-02
PH12015501154B1 (en) 2018-05-30
JO3225B1 (ar) 2018-03-08
EP2925754A1 (en) 2015-10-07
CA2889243C (en) 2017-06-13
SI2925754T1 (sl) 2017-02-28
TWI618705B (zh) 2018-03-21
UA114345C2 (uk) 2017-05-25
MA38126A1 (fr) 2017-03-31
CN104797578B (zh) 2016-11-23
MX2015006697A (es) 2015-08-05
KR101693133B1 (ko) 2017-01-04
SG11201504164VA (en) 2015-07-30
MA38126B1 (fr) 2017-11-30
HRP20170274T1 (hr) 2017-04-07
PT2925754T (pt) 2017-02-27
ZA201503733B (en) 2017-09-27
IL238831A0 (en) 2015-06-30
PH12015501154A1 (en) 2015-08-10
IL238831B (en) 2018-08-30
DK2925754T3 (en) 2017-02-20
JP2016501219A (ja) 2016-01-18
DOP2015000113A (es) 2015-06-15
CY1118657T1 (el) 2017-07-12
US20140148441A1 (en) 2014-05-29
MY177721A (en) 2020-09-23
KR20150070401A (ko) 2015-06-24
EA026686B1 (ru) 2017-05-31
AP2015008489A0 (en) 2015-05-31
CR20150267A (es) 2015-09-16
TW201825484A (zh) 2018-07-16
WO2014085153A1 (en) 2014-06-05
HUE033447T2 (en) 2017-11-28
CN104797578A (zh) 2015-07-22
ES2618260T3 (es) 2017-06-21

Similar Documents

Publication Publication Date Title
AU2013352594B2 (en) 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1H-pyrazol-3-yl}-ethyl)-3H-1,3-benzothiazol-2-one as a TARP-gamma 8 dependent AMPA receptor antagonist
EP2935256B1 (en) 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production
US10000475B2 (en) Triazine carboxamides as sodium channel blockers
WO2019084030A1 (en) (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
WO2019183523A1 (en) Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
CA3103048A1 (en) Oga inhibitor compounds
US20150057300A1 (en) Substituted piperidines as sodium channel blockers
JP2017503837A (ja) ピリジン類及びピリミジン類並びにその使用
JP2024026104A (ja) Ｋｖ７チャネル活性化剤の構成および使用方法
US9376452B2 (en) Rab7 GTPase inhibitors and related methods of treatment
EP3148995B1 (en) 6-substituted-3h-1,3-benzothiazol-2-one compounds as tarp-gamma 8 dependent ampa receptor antagonists
EP3993794A1 (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
CA3197092A1 (en) 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidin e-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia and cancer
HK1209116B (en) 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}-ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist
EP3790885B1 (en) 1-imidazothiadiazolo-2h-pyrrol-5-one derivatives
EP4244219A1 (en) 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxypyrrolidine-2-carboxa mide derivatives as vhl inhibitors for the treatment of anemia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)